Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Izuforant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.88 |
| ▸ | HRH4 | Q9H3N8 | 20/20 | 0.88 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Izuforant SCHEMBL14829381 | 0.98 | HRH4 (0.88) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL29906520 | 0.97 | HRH4 (0.86) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL27075813 | 0.97 | HRH4 (0.86) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL30839510 | 0.94 | HRH4 (0.82) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL27188718 | 0.94 | HRH4 (1.00) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL37560645 | 0.94 | HRH4 (1.00) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL14828792 | 0.94 | HRH4 (1.00) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL30839512 | 0.94 | HRH4 (0.80) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL14829135 | 0.93 | HRH4 (0.98) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL14828927 | 0.93 | HRH4 (0.98) | HRH4HTR3AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594321-A1 | A PROCESS FOR THE MANUFACTURE OF SALTS AND CRYSTALLINE FORMS OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE AND NOVEL CRYSTALLINE FORMS | JW Pharmaceutical Corporation (KR) | 2025-08-06 | — | — | EP | claimed |
| CN-119968370-A | Process for preparing salts and crystalline forms of 1- (8-bromopyrido [2,3-E ] [1,2,4] triazolo [4,3-A ] pyrazin-4-yl) -N-methylazetidin-3-amine and novel crystalline forms | JW制药公司 | 2025-05-09 | — | — | CN | claimed |
| WO-2024068851-A1 | A PROCESS FOR THE MANUFACTURE OF SALTS AND CRYSTALLINE FORMS OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE AND NOVEL CRYSTALLINE FORMS | JW PHARMACEUTICAL CORPORATION (KR) | 2024-04-04 | — | — | WO | claimed |
| EP-3461825-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RES LAB (KR) | 2023-06-07 | — | — | EP | claimed |
| EP-3461825-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C Research Laboratories (KR) | 2019-04-03 | — | — | EP | claimed |
| EP-2760865-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RES LAB (KR) | 2018-07-11 | — | — | EP | claimed |
| US-9586959-B2 | Substituted tricyclic heterocycles as histamine 4 receptor inhibitors | C&C RESEARCH LABORATORIES (KR) | 2017-03-07 | — | — | US | claimed |
| US-20140315888-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RESEARCH LABORATORIES (KR) | 2014-10-23 | — | — | US | claimed |
| EP-2760865-A2 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C Research Laboratories (KR) | 2014-08-06 | — | — | EP | claimed |
| WO-2013048214-A2 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RESEARCH LABORATORIES (KR) | 2013-04-04 | — | — | WO | claimed |
| US-20260103466-A1 | PROCESS FOR THE MANUFACTURE OF SALTS AND CRYSTALLINE FORMS OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-NMETHYLAZETIDIN-3-AMINE AND NOVEL CRYSTALLINE FORMS | JW PHARMACEUTICAL CORP (KR) | 2026-04-16 | — | — | US | disclosed |
| EP-4594321-A1 | A PROCESS FOR THE MANUFACTURE OF SALTS AND CRYSTALLINE FORMS OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE AND NOVEL CRYSTALLINE FORMS | JW Pharmaceutical Corporation (KR) | 2025-08-06 | — | — | EP | disclosed |
| CN-119968370-A | Process for preparing salts and crystalline forms of 1- (8-bromopyrido [2,3-E ] [1,2,4] triazolo [4,3-A ] pyrazin-4-yl) -N-methylazetidin-3-amine and novel crystalline forms | JW制药公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2024068851-A1 | A PROCESS FOR THE MANUFACTURE OF SALTS AND CRYSTALLINE FORMS OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE AND NOVEL CRYSTALLINE FORMS | JW PHARMACEUTICAL CORPORATION (KR) | 2024-04-04 | — | — | WO | disclosed |
| EP-3461825-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RES LAB (KR) | 2023-06-07 | — | — | EP | disclosed |
| EP-2760865-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RES LAB (KR) | 2018-07-11 | — | — | EP | disclosed |
| US-9586959-B2 | Substituted tricyclic heterocycles as histamine 4 receptor inhibitors | C&C RESEARCH LABORATORIES (KR) | 2017-03-07 | — | — | US | disclosed |
| US-20140315888-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RESEARCH LABORATORIES (KR) | 2014-10-23 | — | — | US | disclosed |
| EP-2760865-A2 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C Research Laboratories (KR) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013048214-A2 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RESEARCH LABORATORIES (KR) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103466-A1 | PROCESS FOR THE MANUFACTURE OF SALTS AND CRYSTALLINE FORMS OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-NMETHYLAZETIDIN-3-AMINE AND NOVEL CRYSTALLINE FORMS | HRH4, HRH1, MAST1 | HTR3A 179/4885HRH4 1/4885HRH3 6/4885 |
| US-20140315888-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | HRH4, HRH2, HRH1 | HTR3A 353/4885HRH4 1/4885HRH3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.